213 related articles for article (PubMed ID: 9835496)
1. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
Frankenburg S; Glick D; Klaus S; Barenholz Y
Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
[TBL] [Abstract][Full Text] [Related]
5. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
[TBL] [Abstract][Full Text] [Related]
6. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
7. Failure of amphotericin B lipid complex in the treatment of cutaneous leishmaniasis.
Wortmann GW; Fraser SL; Aronson NE; Davis C; Miller RS; Jackson JD; Oster CN
Clin Infect Dis; 1998 Apr; 26(4):1006-7. PubMed ID: 9564500
[No Abstract] [Full Text] [Related]
8. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
9. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies.
Santos CM; de Oliveira RB; Arantes VT; Caldeira LR; de Oliveira MC; Egito ES; Ferreira LA
J Biomed Nanotechnol; 2012 Apr; 8(2):322-9. PubMed ID: 22515084
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
13. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
[TBL] [Abstract][Full Text] [Related]
14. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.
Cannon JP; Fiscella R; Pattharachayakul S; Garey KW; De Alba F; Piscitelli S; Edward DP; Danziger LH
Invest Ophthalmol Vis Sci; 2003 May; 44(5):2112-7. PubMed ID: 12714650
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
Minodier P; Retornaz K; Horelt A; Garnier JM
Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
[TBL] [Abstract][Full Text] [Related]
17. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
18. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.
Bhamra R; Sa'ad A; Bolcsak LE; Janoff AS; Swenson CE
Antimicrob Agents Chemother; 1997 May; 41(5):886-92. PubMed ID: 9145839
[TBL] [Abstract][Full Text] [Related]
19. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
20. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
Amato VS; Tuon FF; Campos A; Bacha HA; Nicodemo AC; Amato Neto V; Shikanai-Yasuda MA
Clin Infect Dis; 2007 Jan; 44(2):311-2. PubMed ID: 17173238
[No Abstract] [Full Text] [Related]
[Next] [New Search]
